Let's Talk Innovation

Let's Talk
Innovation

You are here

New Immuno-Oncology Lung Cancer Collaboration Launched with Dana-Farber’s Belfer Institute; One of Seven New Strategic Oncology Partnerships

Boston
Innovation Center June 24th, 2014

By Peter Lebowitz, Janssen Global Therapeutic Area Head, Oncology

Today we announced a three-year collaboration with the Dana-Faber Cancer Institute’s Belfer Institute for Applied Cancer Science to determine which lung cancer patients are most likely to benefit from a new generation of immuno-oncology therapies.  This agreement is one of seven new strategic oncology collaborations that we’ve recently announced, including a lymphoma program with Weill Cornell Medical College, a prostate cancer focused agreement with Aduro BioTech, and targeted antibody program agreements with the companies Bioceros, Merus, and Affimed.

Together, these new collaborations demonstrate the Janssen commitment to patients by pursuing the best science internally and externally.  They also reflect the transformative approaches being sought by Johnson & Johnson Innovation and Janssen across three main oncology focus areas: lung cancer, prostate cancer, and hematological malignancies.

Our goal in the Dana-Farber agreement, as well as in the MD Anderson Cancer Center collaboration we announced earlier this year, is to develop personalized medicine approaches using immuno-oncology therapies. Immuno-oncology therapies are an exciting approach to treating cancer by harnessing a patient’s own immune system to attack tumors, potentially resulting in a durable response.

As noted by Kwok-Kin Wong, MD, PhD, co-scientific director of the Belfer Institute, “Immuno-oncology therapies have yielded dramatic and durable responses in subsets of cancer patients.  In lung cancer, there is a tremendous opportunity to enhance patient outcomes by understanding why some patients respond to these agents while others don’t.”

The Dana-Farber collaboration leverages the Belfer Institute’s lung cancer research platform and unique models to assess new immuno-oncology therapy agents in conditions that simulate the physical environment of human lung tumors.  The collaboration will evaluate the most effective ways of combining immuno-oncology therapy drugs, identify biomarkers and explore the biological mechanisms behind drug resistance.

The collaboration with MD Anderson similarly leverages unique clinical research capabilities to understand the immune system microenvironment and to identify new opportunities for therapeutic interventions.

A significant feature of both of these collaborations is the close connection between Janssen researchers with the scientific teams at both Dana-Farber and MD Anderson Cancer Center.  These connections ensure the swiftest possible progress for patients, which in the end, is what really matters most.

Add new comment

Leave a comment

You agree that the information you provide will be governed by our Privacy Policy.
Your email address and last name will not be displayed publicly with your comment.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

We reserve the right to not post any comment that is considered inappropriate, off-topic, abusive, or that is used to promote and solicit for third party sites, initiatives, or products. All comments will be reviewed and may not be posted if deemed inappropriate. Approved comments may take up to 72 hours after they are received to be posted.

This Blog is not intended to be a place to report customer service, adverse events or product quality complaints. We take adverse events and product quality complaints very seriously. To report an adverse event or product quality complaint, please send us a message at jnjinnovation@its.jnj.com.